WS Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

WS Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-80,650	Closed	-$395K	–	83
2022 Q3	$395K	Hold	80,650	–	–	0.04%	66
2022 Q2	$334K	Hold	80,650	–	–	0.03%	71
2022 Q1	$469K	Hold	80,650	–	–	0.02%	65
2021 Q4	$605K	Hold	80,650	–	–	0.05%	58
2021 Q3	$727K	Hold	80,650	–	–	0.08%	65
2021 Q2	$965K	Hold	80,650	–	–	0.1%	68
2021 Q1	$1.01M	Sell	80,650 -4,161	-5%	-$56.1K	0.1%	60
2020 Q4	$1.32M	Hold	84,811	–	–	0.14%	50
2020 Q3	$801K	Hold	84,811	–	–	0.09%	58
2020 Q2	$760K	Sell	84,811 -14,509	-15%	-$135K	0.09%	51
2020 Q1	$633K	Sell	99,320 -4,968	-5%	-$36.9K	0.07%	59
2019 Q4	$873K	Hold	104,288	–	–	0.07%	52
2019 Q3	$944K	Sell	104,288 -11,451	-10%	-$128K	0.07%	57
2019 Q2	$1.25M	Sell	115,739 -13,633	-11%	-$145K	0.08%	60
2019 Q1	$1.23M	Sell	129,372 -17,368	-12%	-$177K	0.07%	59
2018 Q4	$1.69M	Sell	146,740 -96,260	-40%	-$1.2M	0.08%	66
2018 Q3	$4.12M	Hold	243,000	–	–	0.14%	67
2018 Q2	$3.45M	Buy	+243,000	New	+$4.04M	0.1%	70

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WS Management's SGMO Position: Q4 2022 in Review

WS Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2022, closing a stake of 80,650 shares — an estimated $395K sold.

WS Management first reported a position in SGMO in Q2 2018 and held it in 18 quarters. The position peaked at $4.12M in Q3 2018. 182 funds tracked by Wall St. Rank hold SGMO as of Q4 2022.

WS Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2022 after selling out during the quarter.
WS Management sold 80,650 SANGAMO THERAPEUTICS INC shares in Q4 2022, an estimated $395K.
WS Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and held it in 18 quarters.
WS Management's SANGAMO THERAPEUTICS INC position peaked at $4.12M in Q3 2018.
182 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2022.

Based on WS Management's 13F filing for Q4 2022, filed 14 Feb 2023.